Moderna‘s (NASDAQ:MRNA | MRNA Price Prediction) acquisition currency just changed complexion. The stock closed at $174.38 on August 19, 2026, a single-session gain of 176.9% that lifted the market capitalization to roughly $69.6 billion. Management still guided to a year-end 2026 cash and investments balance of between $4.7 billion and $5.2 billion, plus an undrawn $0.9 billion credit facility. The $950 million Arbutus/Genevant settlement is largely resolved for Moderna.
CEO Stéphane Bancel told investors Moderna is preparing for “the growth stage of a company coming ahead of us.” Management has not signaled M&A intent; no deal has been reported.
1. Immatics: The Partner Already Inside the Tent
Immatics (NASDAQ:IMTX) has a $1.3 billion market cap. Moderna already triggered a $5 million milestone in January 2026 for advancing a shared antigen candidate. Anzu-cel is in Phase 3 SUPRAME for cutaneous melanoma, with BLA submission targeted 2027. Existing collaborations are the strongest real-world predictor of acquisition. Diligence is largely done, and it doubles down on the Merck-partnered intismeran melanoma thesis.
2. Arbutus: Buy the Landlord
Arbutus Biopharma (NASDAQ:ABUS) carries a $957.6 million cap. Moderna just paid Arbutus $178.4 million of the settlement, with $1.3 billion in contingent exposure pending appellate ruling. Arbutus and its licensee Genevant hold the LNP IP Moderna’s platform relies on and are litigating against Pfizer and BioNTech in 21 countries. Acquiring Arbutus would extinguish the tail risk and put Moderna on the enforcement side of the litigation.
3. Intellia: First In Vivo CRISPR Launch
Intellia Therapeutics (NASDAQ:NTLA), at a $1.9 billion market cap, offers lonvo-z for hereditary angioedema. Phase 3 HAELO showed an 87% reduction in attacks versus placebo, with 62% of patients attack-free and therapy-free. U.S. launch is targeted for H1 2027. The complication: nex-z is co-developed with Regeneron, which encumbers a clean takeout.
4. Editas: The Cheap Optionality Bet
Editas Medicine (NASDAQ:EDIT), at $442.3 million, is the smallest. EDIT-401 delivered >90% reductions in LDL-C, Lp(a), and ApoB in non-human primates, with Phase 1/2 topline data expected in 2027. It opens a cardiometabolic vertical at a fraction of the cost relative to Moderna’s available capital.
The Field Is Consolidating Around mRNA and Genetic Medicine
The mRNA and genetic medicine field is already consolidating, with BioNTech completing its acquisition of CureVac, Eli Lilly acquiring Orna Therapeutics, and Vertex Pharmaceuticals completing a buyout of Crinetics Pharmaceuticals. Now, Moderna is a bidder whose currency just strengthened.
However, keep in mind that a stock that just re-rated on a single clinical readout may prefer to fund its own pipeline, and Bancel has explicitly emphasized “financial discipline.”
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks